Apoptosis and autoimmunity

Immunologic Research

Volumn 36, Issue 1-3, 2006, Pages 3-12

  Navratil, Jeannine S ^b   Liu, Chau Ching ^b   Ahearn, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Apoptosis; Autoantibody; Autoantigen; Autoimmunity; Complement; SLE; Tolerance

Indexed keywords

AUTOANTIGEN; COMPLEMENT; COMPLEMENT RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; COMPLEMENT CLASSICAL PATHWAY; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW;

EID: 33947159798     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:36:1:3     Document Type: Review

References (84)

1. Hengartner MO: The biochemistry of apoptotis. Nature 2000;407:770-776.
2. Thornberry NA: Caspases: enemies within. Science 1998;281:1312-1316.
3. Utz PJ, Hottelet M, Schur PH, Anderson P: Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997;185:843-854.
4. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330.
5. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-2216.
6. Navratil JS, Sabatine JM, Ahearn JM: Apoptosis and immune responses to self. Rheum Dis Clin N Am 2004;30:193-212.
7. Hall JC, Casciola-Rosen L, Rosen A: Altered structure of autoantigens during apoptosis. Rheum Dis Clin N Am 2004;30:455-471.
8. Sercarz EE: Processing creates the self. Nat Immunol 2002;3:110-112.
9. Casciola-Rosen LA, Anhalt GJ, Rosen A: DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 1995;182:1625-1634.
10. Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A: Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem 1994;269:30757-30760.
11. Casiano CA, Martin SJ, Green DR, Tan EM: Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-770.
12. Caulin C, Salvesen G, Oshima R: Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cells apoptosis. J Cell Biol 1997;138:1379-1394.
13. Hsu HL, Yeh NH: Dynamic changes of NuMA during the cell cycle and possible appearance of a truncated form of NuMA during apoptosis. J Cell Sci 1996;109:277-288.
14. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346-347.
15. Neamati N, Fernandez A, Wright S, Kiefer J, McConkey DJ: Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol 1995;154:3788-3795.
16. Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M: Chromatin condensation during apoptosis is accompanied by degradation of lamin A + B without enhanced activation of cdc2 kinase. J Cell Biol 1994;126:827-837.
17. Piedrafita F, Pfahl M: Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 1997;17:6348-6358.
18. Weaver VM, Carson EC, Walker PR, et al: Degradation of nuclear matrix and DNA cleavage in apoptotic thymocytes. J Cell Sci 1996;109:45-56.
19. Utz PJ, Hottelet M, Le TM, et al: The 72-kDa component of signal recognition particle is cleaved during apoptosis. J Biol Chem 1998;273:35362-35370.
20. Rutjes SA, Utz PJ, van der Heijden A, Broekhuis C, van Venrooij WJ, Pruijn GJM: The La(SS-B) autoantigen, a key protein in RNA biogenesis, is dephosphorylated and cleaved early during apoptosis. Cell Death Differ 1999;6:976-986.
21. Van Parijs L, Abbas AK: Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998;280:243-248.
22. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994;76:977-987.
23. Shi L, Kam CM, Powers JC, R A, Greenberg AH: Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med 1992;176:1521-1529.
24. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L: Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998;8:451-460.
25. Casciola-Rosen LA, Andrade F, Ulanet D, Wong WB, Rosen A: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-825.
26. Casciola-Rosen LA, Pluta AF, Cox AE, et al: The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001;44:389-396.
27. Nagaraju K, Cox A, Casciola-Rosen L, Rosen A: Novel fragments of the Sjögren's syndrome autoantigens α-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 2001;44:2376-2386.
28. Schachna L, Wigley FM, Morris S, Gelber AC, Rosen A, Casciola-Rosen L: Recognition of granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum 2002;46:1873-1884.
29. Ulanet DB, Flavahan NA, Casciola-Rosen L, Rosen A: Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis Rheum 2004;50:233-241.
30. Graham KL, Utz PJ: Sources of autoagntigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:513-517.
31. Rosen A, Casciola-Rosen L, Ahearn J: Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med 1995;181:1557-1561.
32. Greidinger EL, Casciola-Rosen L, Morris SM, Hoffman RW, Rosen A: Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations. Arthritis Rheum 2000;43:881-888.
33. Rosen A, Casciola-Rosen L, Wigley F: Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheum 1997;9:538-543.
34. Gerl V, Hostmann B, Johnen C, et al: The intracellular 50-kd Ro/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor α via tumor necrosis factor receptor I. Arthritis Rheum 2005;52:531-538.
35. LeFeber WP, Norris DA, Ryan SR, et al: Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 1984;74:1545-1551.
36. Miranda ME, Tseng C, Rashbaum W, et al: Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol 1998;161:5061-5069.
37. Tran HB, Ohlsson M, Beroukas D, et al: Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum 2002;46:202-208.
38. Clancy RM, Kapur RP, Molad Y, Askanase AD, Buyon JP: Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004;50:173-182.
39. Casciola-Rosen L, Rosen A, Petri M, Schlissel M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996;93:1624-1629.
40. Rauch J, Subang R, D'Agnillo P, Koh JS, Levine JS: Apoptosis and the antiphospholipid syndrome. J Autoimmunity 2000;15:231-235.
41. Stach CM, Turnay X, Voll RE, et al: Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balbc mice. Cell Death Differ 2000;7:911-915.
42. Levine JS, Subang R, Koh JS, J R: Induction of antiphopholipid antibodies by β2-glycoprotein-I bound to apoptotic thymocytes. J Autoimmunity 1998;11:413-424.
43. Subang R, Levine JS, Janoff AS, et al: Phospholipid-bound β2-glycoprotein I induces the production of antiphosopholipid antibodies. J Autoimmunity 2000;15:21-32.
44. Price BE, Rauch J, Shia MA, et al: Antiphospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J Immunol 1996;157:2201-2208.
45. Rovere P, Sabbadini MG, Vallinoto C, et al: Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory comtext: role of opsonizing anti-β2-glycoprotein I antibodies. Arthritis Rheum 1999;42:1412-1420.
46. Korb LC, Ahearn JM: C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. Complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997;158:4525-4528.
47. Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM: The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001;166:3231-3239.
48. Wener MH, Uwatoko S, Mannik M: Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum 1989;32:544-551.
49. Wisnieski JJ, Baer AN, Christensen J, et al: Hypocomplementemic urticarial vasculitis syndrome: clinical and serologic findings in 18 patients. Medicine 1995;74:24-41.
50. Steinman RM, Turley S, Mellman I, Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-416.
51. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
52. Albert ML, Pearce SFA, Francisco LM, et al: Immature dendritic cells phagocytose apoptotic cells via αVβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-1368.
53. Ronchetti A, Iezzi G, Crosti MC, Garancini MP, Protti MP, Bellone M: Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. J Leukocyte Biol 1999;66:247-251.
54. Rovere P, Sabbadini MG, Vallinoto C, et al: Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukocyte Biol 1999;66:345-349.
55. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M: Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59:3329-3332.
56. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL: Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542-3549.
57. Larsson M, Fonteneau J-F, Somersan S, et al: Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001;31:3432-3442.
58. Zhao XQ, Huang XL, Gupta P, et al: Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8+ and CD4+ T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells. J Virol 2002;76:3007-3014.
59. Mevorach D, Zhou JL, Song X, Elkon KB: Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-392.
60. Gensler TJ, Hottelet M, Zhang C, Schlossman S, Anderson P, Utz PJ: Monoclonal antibodies derived from BALB/c mice immunized with apoptotic jurkat T cells recognize known autoantigens. J Autoimmunity 2001;16:59-69.
61. Savill J, Dransfield I, Gregory C, Haslett C: A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2:965-975.
62. Nauta AJ, Trouw LA, Daha MR, et al: Direct binding of C1q to apoptotic cells and cell blebs induces complemen activation. Eur J Immunol 2002;32:1726-1736.
63. Botto M, Dell'Agnola C, Bygrave AE, et al: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-59.
64. Taylor PR, Carugati A, Fadok VA, et al: A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000;192:359-366.
65. Reid KB, Porter RR: Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J 1976;155:19-23.
66. Elward K, Griffiths M, Mizuno M, et al: CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005;280:36342-36354.
67. Jiang H, Cooper B, Robey FA, Gewurz H: DNA binds and activates complement via residues 14-26 of the human C1q A chain. J Biol Chem 1992;267:25597-25601.
68. 2 activation during apoptosis promotes the exposure of membrane lysophosphatidylocholine leading to binding by natural immunoglobulin A antibodies and complement activation. J Exp Med 2002;196:655-665.
69. Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M: Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 2004;35:252-260.
70. Boes M, Schmidt T, Linkermann K, Beaudette BC, Marshak-Rothstein A, Chen J: Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000;97:1184-1189.
71. Ehrenstein MR, Cook HT, Neuberger MS: Deficiency in serum immunoglogulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 2000;191:1253-1258.
72. P, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J Immunol 1998;160:1929-1935.
73. Malhotra R, Thail S, Reid KBM, Sim RB: Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990;172:955-959.
74. Ogden CA, deCathelineau A, Hoffmann PR, et al: C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001;194:781-795.
75. Vandivier RW, Ogden CA, Fadok VA, et al: Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 2002;169:3978-3986.
76. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A: Complement receptor type I (CR1, CD35) is a receptor for C1q. Immunity 1997;7:345-355.
77. Navratil JS, Zurowski NB, Ahearn JM: Apoptotic endothelial cells and PBMC are tagged specifically by C3- and C4-derived ligands during membrane loss of RCA proteins: implications for immune tolerance and pathogenesis of SLE [Abstract 100]. Immunopharmacology 2000;49:36.
78. Zurowski NB, Navratil JS, Ursu S, Nosce R, Ahearn JA: Ultraviolet B (UVB) induces apoptosis and deposition of C3- and C4- derived ligands on primary human and murine keratinocytes in vivo: implications for immune tolerance and the pathogenesis of SLE [Abstract 99]. Immunopharmacology 2000;49:36.
79. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB: Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998;188:2313-2320.
80. Gershov D, Kim SJ, Brot N, Elkon KB: C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-1363.
81. Verbovetski I, Bychkov H, Trahtemberg U, et al: Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, downregulates DR and CD86, and up-regulates CC chemokine receptor 7. J Exp Med 2002;196:1553-1561.
82. Morelli AE, Larregina AT, Shufesky WJ, et al: Internalization of circulating apoptotic cells by splenic marginal zone dencritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003;101:611-620.
83. Ahearn JM, Rosengard AM: Complement receptors, in Volanakis JE, Frank MM (eds): The Human Complement System in Health and Disease. New York, Marcel Dekker, 1998, pp. 167-202.
84. Walport MJ, Lachmann PJ: Erythrocyte complement receptor type 1, immune complexes and the rheumatic diseases. Arthritis Rheum 1987;31:153-158.